New program aims to protect cancer patients' hearts during active treatment
NCT ID NCT06834204
First seen Feb 28, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This study tests a program called Primary Care Connect (PC2) that helps cancer survivors with heart risks stay connected to their primary care doctor during cancer treatment. About 266 adults with early-stage breast, prostate, bladder, or endometrial cancer who also have high blood pressure, diabetes, or high cholesterol will take part. The goal is to see if the program improves management of these chronic conditions and reduces heart disease risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rutgers RWJ Medical School
Somerset, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.